Another point - blind is not because of weak data - normally it is done when there are safety issues and in case of very long trials such as Alz or cancer and they find that it is futile to proceed further.
This is a short trial - tge results may not be futile but may be not as attractive - safety was established so there was not need to unblind the data but maybe reason enough not to share